Adult antiretroviral therapy guidelines 2017

These guidelines are intended as an update to those published in the Southern African Journal of HIV Medicine in 2014 and the update on when to initiate antiretroviral therapy in 2015. Since the release of the previous guidelines, the scale-up of antiretroviral therapy (ART) in southern Africa has continued. New antiretroviral drugs have become available with improved efficacy, safety and robustness. The guidelines are intended for countries in the southern African region, which vary between lower and middle income.

[1]  A. Zolopa,et al.  Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial , 2009, PloS one.

[2]  I. Sanne,et al.  Will etravirine work in patients failing nonnucleoside reverse transcriptase inhibitor-based treatment in southern Africa? , 2009, Journal of acquired immune deficiency syndromes.

[3]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[4]  N. Ford,et al.  The future role of CD4 cell count for monitoring antiretroviral therapy. , 2015, The Lancet. Infectious diseases.

[5]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[6]  D. Podzamczer,et al.  Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial , 2015, Journal of acquired immune deficiency syndromes.

[7]  Ming-yuan Li,et al.  Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials , 2016, PloS one.

[8]  D. Boulware,et al.  Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. , 2014, The New England journal of medicine.

[9]  R. Salamon,et al.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.

[10]  C. Mengoli,et al.  Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data , 2011, AIDS.

[11]  G. Maartens,et al.  Systematic Review of Antiretroviral-Associated Lipodystrophy: Lipoatrophy, but Not Central Fat Gain, Is an Antiretroviral Adverse Drug Reaction , 2013, PloS one.

[12]  M. Battegay,et al.  Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  G. Maartens,et al.  Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study , 2015, AIDS Research and Therapy.

[14]  C. Katlama,et al.  High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Justen Manasa,et al.  Primary drug resistance in South Africa: data from 10 years of surveys. , 2012, AIDS research and human retroviruses.

[16]  J. Nachega,et al.  Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis , 2015, Annals of Internal Medicine.

[17]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[18]  Michael Rayment,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.

[19]  G. Meintjes,et al.  A practical approach to the diagnosis and management of paradoxical tuberculosis immune reconstitution inflammatory syndrome , 2013 .

[20]  C. Yiannoutsos,et al.  Mortality Associated With Discordant Responses to Antiretroviral Therapy in Resource-Constrained Settings , 2010, Journal of acquired immune deficiency syndromes.

[21]  B. Thiers,et al.  CD4+ Count–Guided Interruption of Antiretroviral Treatment , 2007 .

[22]  Clare Brennan,et al.  Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study , 2013, The Lancet.

[23]  J. Macías,et al.  Gynaecomastia in HIV-Infected Men on Highly Active Antiretroviral Therapy: Association with Efavirenz and Didanosine Treatment , 2004, Antiviral therapy.

[24]  M. Johnson,et al.  96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures , 2006, AIDS.

[25]  R. Bertz,et al.  Atazanavir Pharmacokinetics, Efficacy and Safety in Pregnancy: A Systematic Review , 2013, Antiviral therapy.

[26]  J. Mellors,et al.  Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. , 2016, The lancet. HIV.

[27]  JD Lundgren,et al.  Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study , 2007, The Lancet.

[28]  G. Maartens,et al.  Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa , 2016, AIDS Research and Therapy.

[29]  V. Calvez,et al.  Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy , 2010, AIDS.

[30]  J. Gallant,et al.  Antiretroviral Therapy for the Prevention of HIV-1 Transmission. , 2016, The New England journal of medicine.

[31]  M. J. van der Laan,et al.  Virologic efficacy of boosted double versus boosted single protease inhibitor therapy , 2007, AIDS.

[32]  H. Hatano,et al.  The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting , 2017, Journal of acquired immune deficiency syndromes.

[33]  B. Clotet,et al.  Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. , 2015, The lancet. HIV.

[34]  J. Absalon,et al.  Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study , 2010, Journal of acquired immune deficiency syndromes.

[35]  Richard D Moore,et al.  Elite Controllers are Hospitalized More Often than Persons with Medically Controlled HIV , 2014 .

[36]  C. Mengoli,et al.  Virological efficacy of abacavir: systematic review and meta-analysis. , 2014, The Journal of antimicrobial chemotherapy.

[37]  O. Kirk,et al.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.

[38]  J. Lok,et al.  No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  Z. Desta,et al.  Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth , 2010, HIV medicine.

[40]  M. Hudgens,et al.  Protein Binding of Lopinavir and Ritonavir During 4 Phases of Pregnancy: Implications for Treatment Guidelines , 2013, Journal of acquired immune deficiency syndromes.

[41]  C. Flexner,et al.  Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs. , 2016, The Journal of antimicrobial chemotherapy.

[42]  Bruno Ledergerber,et al.  Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes , 2004, The Lancet.

[43]  L. Richeldi,et al.  Rifabutin for treating pulmonary tuberculosis. , 2007, The Cochrane database of systematic reviews.

[44]  R. Hogg,et al.  A CD4+ Cell Count <200 Cells per Cubic Millimeter at 2 Years After Initiation of Combination Antiretroviral Therapy Is Associated With Increased Mortality in HIV-Infected Individuals With Viral Suppression , 2010, Journal of acquired immune deficiency syndromes.

[45]  J. Tucker,et al.  Social and ethical implications of HIV cure research , 2014, AIDS.

[46]  J. Farrar,et al.  Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  P. Cahn,et al.  Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study , 2013, The Lancet.

[48]  G. Eliopoulos,et al.  The Sanford guide to antimicrobial therapy , 2010 .

[49]  B. Gazzard,et al.  Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial , 2014, The Lancet.

[50]  P. Reiss,et al.  Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. , 2008, The Lancet. Infectious diseases.

[51]  M. Markowitz,et al.  Should We Treat Acute HIV Infection? , 2012, Current HIV/AIDS Reports.

[52]  D. Glidden,et al.  Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial. , 2016, The lancet. HIV.

[53]  S. Lawn,et al.  Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies , 2011, PLoS medicine.

[54]  Beth Chaplin,et al.  Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  G. Maartens,et al.  Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial , 2014, The Lancet.

[56]  M. Setshedi,et al.  Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa , 2016, AIDS.

[57]  L. Haddow,et al.  Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. , 2010, The Lancet. Infectious diseases.

[58]  R. Peeling,et al.  Optimal strategies for monitoring response to antiretroviral therapy in HIV-infected adults, adolescents, children and pregnant women: a systematic review , 2014, AIDS.

[59]  H. Stellbrink,et al.  Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials , 2013, AIDS.

[60]  R. Lempicki,et al.  Evidence for innate immune system activation in HIV type 1-infected elite controllers. , 2014, The Journal of infectious diseases.

[61]  E. Soliman,et al.  Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. , 2011, Journal of electrocardiology.

[62]  M. Shlipak,et al.  Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  G. Maartens,et al.  Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome , 2010, AIDS.

[64]  A. Puren,et al.  Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[65]  M. Fox,et al.  Initiating Antiretroviral Therapy for HIV at a Patient’s First Clinic Visit: The RapIT Randomized Controlled Trial , 2016, PLoS medicine.

[66]  M. Egger,et al.  Life Expectancies of South African Adults Starting Antiretroviral Treatment: Collaborative Analysis of Cohort Studies , 2013, PLoS medicine.

[67]  Richard D Moore,et al.  Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection. , 2014, The Journal of infectious diseases.

[68]  Caroline A Sabin,et al.  The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy , 2003, AIDS.

[69]  P. Easterbrook,et al.  Assessment of second-line antiretroviral regimens for HIV therapy in Africa. , 2014, The New England journal of medicine.

[70]  C. Delaugerre,et al.  Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. , 2014, The Lancet. Infectious diseases.

[71]  N. Ford,et al.  Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis , 2011, AIDS.